| abstract |
Use of a combination of a topical R, R-glycopyrrolate or a physiologically acceptable salt thereof with PDE 4 phosphodiesterase inhibitors selected from the group consisting of rolipram, roflumilast or their physiologically acceptable salts for the manufacture of a medicament for the treatment of bronchial asthma or chronic obstructive pulmonary disease lungs (COPD). The patent contains 9 more patent claims. |